timothy sykes logo
Personalis Stock Jumps As Tempus AI Acquisition Reshapes Trade Setup Thumbnail
G Google News

Personalis Stock Jumps As Tempus AI Acquisition Reshapes Trade Setup

ELLIS HOBBS•UPDATED AUG. 23, 2026, 11:07 AM ET
Reviewed by Jack Kelloggand Fact-checked by Tim Sykes

Personalis Inc. stocks have been trading up by 9.41 percent following investor optimism around its latest precision oncology advances.

What Traders Need To Know

  • Q2 revenue came in at $22.4M, well ahead of the $16.7M consensus, signaling strong near-term execution.
  • Clinical volume for the NeXT Personal MRD test surged 199% year over year and 33% sequentially, backing guidance for over 500% clinical revenue growth in 2026.
  • The company agreed to be acquired by Tempus AI for $16.25 per share in a deal variously described as all cash or all stock with an option for up to 50% cash, with a floating Tempus share exchange cap at 0.3356.
  • After the July 20, 2026 merger agreement, management will no longer issue guidance or hold earnings calls, shifting focus from quarterly execution to deal closure.
  • Multiple shareholder-rights law firms are challenging whether the $16.25 offer fairly values Personalis and whether the sale process, structure, and disclosures properly protect PSNL shareholders.

Candlestick Chart

Weekly Update Aug 17 – Aug 21, 2026: On Sunday, August 23, 2026 Personalis Inc. stock [NASDAQ: PSNL] is trending up by 9.41%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Healthcare industry expert:

Analyst sentiment – positive

Personalis sits in a niche but strategically valuable MRD-driven oncology testing position, with strong 63% gross margin but extremely weak profitability (EBIT margin roughly -150% and ROE near -50%). Revenue at ~$69.6M with mixed multi‑year CAGR and quarterly Q2 sales of $22.4M show reacceleration from NeXT Personal, but scale remains subscale versus leading diagnostics peers. Liquidity is solid (current ratio 5.3, net cash ~+$63M, low leverage), yet free cash flow at -$29.6M underscores ongoing external capital dependence.

Technically, PSNL has broken sharply higher following the Tempus AI takeout, with a weekly move from $13.77 to $18.47 and an accelerating series of higher highs and higher lows, confirming a powerful new uptrend. Intraday 5‑minute action shows consolidation above $18 with rising volume on upticks, indicating active event‑driven buyers rather than organic accumulation. The single key actionable level is $16.25: any pullback toward that area should be viewed as primary support and likely defended by merger‑arb flows.

The Tempus acquisition at $16.25 per share now dominates the thesis; Personalis has stopped guidance and calls, effectively capping standalone information flow. PSNL now trades above the deal price, reflecting market expectation of either a bump, competing interest, or perceived underpricing of MRD growth prospects versus diagnostics peers. Regulatory and shareholder‑rights reviews are the main remaining catalysts. Base‑case fair value aligns near $16–18 with $16.25 as firm support and $18.50 as near‑term resistance.

More Breaking News

Quick Financial Overview

Personalis Inc. is being taken out just as its operating story inflects. Q2 revenue of $22.4M beat the $16.7M consensus by a wide margin, and the NeXT Personal MRD cancer test delivered a 199% year-over-year and 33% sequential jump in clinical testing volume. Management is guiding to more than 500% clinical revenue growth for the full year, which means the Tempus AI deal lands while the core clinical engine is accelerating, not stalling.

Under the hood, PSNL is still a heavy loss-maker. The latest quarter shows total revenue of about $22.4M against a net loss of roughly $31.7M, with EBIT margin near -153.5% and profit margins deeply negative. A strong 63.3% gross margin and minimal leverage (total debt-to-equity around 0.13, current ratio near 5.3) give the company time, but negative return on equity near -50% and free cash flow around -$29.6M confirm it is burning cash to chase growth.

The tape now trades like a deal story. Weekly prices ramped from the mid-$13s to roughly $18.47, moving through the $16.25 offer and signaling traders are already pricing some bump or deal optionality. Intraday, a 5‑minute candle that ran from the mid-$16s to a high near $18.89 before settling around $18.38 shows aggressive buy demand as the market digested both the earnings beat and the Tempus bid. For short-term traders, the key battleground is whether PSNL can keep holding above the $16.25 floor while speculation around legal challenges and potential sweeteners plays out.

Conclusion

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:

How much has this post helped you?

(0 votes, average: 0 out of 5)
Leave a reply

* Results are not typical and will vary from person to person. Making money trading stocks takes time, dedication, and hard work. There are inherent risks involved with investing in the stock market, including the loss of your investment. Past performance in the market is not indicative of future results. Any investment is at your own risk. See Terms of Service here

The available research on day trading suggests that most active traders lose money. Fees and overtrading are major contributors to these losses.

A 2000 study called “Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors” evaluated 66,465 U.S. households that held stocks from 1991 to 1996. The households that traded most averaged an 11.4% annual return during a period where the overall market gained 17.9%. These lower returns were attributed to overconfidence.

A 2014 paper (revised 2019) titled “Learning Fast or Slow?” analyzed the complete transaction history of the Taiwan Stock Exchange between 1992 and 2006. It looked at the ongoing performance of day traders in this sample, and found that 97% of day traders can expect to lose money from trading, and more than 90% of all day trading volume can be traced to investors who predictably lose money. Additionally, it tied the behavior of gamblers and drivers who get more speeding tickets to overtrading, and cited studies showing that legalized gambling has an inverse effect on trading volume.

A 2019 research study (revised 2020) called “Day Trading for a Living?” observed 19,646 Brazilian futures contract traders who started day trading from 2013 to 2015, and recorded two years of their trading activity. The study authors found that 97% of traders with more than 300 days actively trading lost money, and only 1.1% earned more than the Brazilian minimum wage ($16 USD per day). They hypothesized that the greater returns shown in previous studies did not differentiate between frequent day traders and those who traded rarely, and that more frequent trading activity decreases the chance of profitability.

These studies show the wide variance of the available data on day trading profitability. One thing that seems clear from the research is that most day traders lose money .

Millionaire Media 66 W Flagler St. Ste. 900 Miami, FL 33130 United States (888) 878-3621 This is for information purposes only as Millionaire Media LLC nor Timothy Sykes is registered as a securities broker-dealer or an investment adviser. No information herein is intended as securities brokerage, investment, tax, accounting or legal advice, as an offer or solicitation of an offer to sell or buy, or as an endorsement, recommendation or sponsorship of any company, security or fund. Millionaire Media LLC and Timothy Sykes cannot and does not assess, verify or guarantee the adequacy, accuracy or completeness of any information, the suitability or profitability of any particular investment, or the potential value of any investment or informational source. The reader bears responsibility for his/her own investment research and decisions, should seek the advice of a qualified securities professional before making any investment, and investigate and fully understand any and all risks before investing. Millionaire Media LLC and Timothy Sykes in no way warrants the solvency, financial condition, or investment advisability of any of the securities mentioned in communications or websites. In addition, Millionaire Media LLC and Timothy Sykes accepts no liability whatsoever for any direct or consequential loss arising from any use of this information. This information is not intended to be used as the sole basis of any investment decision, nor should it be construed as advice designed to meet the investment needs of any particular investor. Past performance is not necessarily indicative of future returns.

Citations for Disclaimer

Barber, Brad M. and Odean, Terrance, Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors. Available at SSRN: “Day Trading for a Living?”

Barber, Brad M. and Lee, Yi-Tsung and Liu, Yu-Jane and Odean, Terrance and Zhang, Ke, Learning Fast or Slow? (May 28, 2019). Forthcoming: Review of Asset Pricing Studies, Available at SSRN: “https://ssrn.com/abstract=2535636”

Chague, Fernando and De-Losso, Rodrigo and Giovannetti, Bruno, Day Trading for a Living? (June 11, 2020). Available at SSRN: “https://ssrn.com/abstract=3423101”